ROBOSENSE-LIDAR
29.7.2021 14:02:14 CEST | Business Wire | Press release
RoboSense LiDAR , the leading Smart LiDAR Sensor provider and GAC Aion New Energy Automobile Co., Ltd. (“GAC Aion”) set up by Guangzhou Automobile Group Co., Ltd (GAC Group，6601238.SH，02238.HK) , a Fortune 500 company and one of the automobile groups with the most complete industry chain in China jointly announced that GAC has selected RoboSense's second-generation intelligent solid-state LiDAR equipped with the ADiGO autonomous driving system，and will be mass-produced on a variety of autonomous driving models including the Aion LX of GAC Aion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005558/en/
ADiGO is an intelligent driving ecosystem led by GAC. This independently developed and interconnected ecosystem integrates smart factory, autopilot system, and IoT system. Powered by big data and various AI technologies, the self-driving system is available for mass production in L3 and is able to support L4 pilot running in some closed scenarios. The current ADiGO system on the Aion LX and Aion V uses a triple perception system (camera, millimeter wave radar, high-precision map) to achieve L3 autonomous driving in highway and urban expressway scenes.
The characteristics of Robosense's second-generation LiDAR active high-precision three-dimensional perception allows the ADiGO system to obtain more reliable perception information and ensure driving safety. It adopts a revolutionary two-dimensional MEMS smart chip scanning architecture and has a unique intelligent "GAZE" function, which can adjust the scanning method according to the driving scene, improve the perception of LiDAR, and help improve the performance and experience of autonomous driving. While achieving hardware intelligence verification, RS-LiDAR-Algorithm, the core of software intelligence, has more than 13-years of technology research and development accumulation. During the 5-year commercialization of LiDAR products, it has been verified by more than 100 partners in multiple scenarios around the world. Internally integrated AI perception algorithm, synchronously output 3D point cloud data and target-level environment perception results. The second-generation intelligent solid-state LiDAR helps the ADiGO system achieve a leap from safety to comfort in the driving experience under various road conditions.
In high-speed scenes, intelligent “GAZE” dynamically increases the vertical resolution of the ROI area, allowing the ADiGO system to find distant obstacles earlier, and enhance the autonomous driving experience on highways and urban expressways. In urban scenes, intelligent “GAZE” dynamically improves refresh the frame rate helps the ADiGO system respond more quickly to the dynamic changes of surrounding vehicles，pedestrians and other obstacles.
Due to technological innovation, the second-generation intelligent LiDAR can effectively control hardware costs, allowing more consumers to obtain a safer and more comfortable experience of autonomous driving. In the future, RoboSense will continue to promote technological innovation. Through the sustainable upgrad of intelligent LiDAR product system solution, it will work with partners to promote the intelligent car ecosystem.
About RoboSense (www.robosense.ai ):
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world leading provider of Smart LiDAR Sensor Systems. It incorporates LiDAR sensors, AI algorithms and IC chipsets that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. The company's mission is to produce outstanding hardware and artificial intelligence capabilities to provide smart solutions that enable robots (including vehicles) to have perception capability superior to humans.
About GAC Motor (https://www.gac-motor.com ):
Guangzhou Automobile Group Co., Ltd. (“GAC”) was incorporated in June 1997. In 2020, GAC’s production and sales both exceeded 2 million, with a positive year-on-year growth. Based on export planning, GAC Group successfully pushed ahead its international business, and GAC MOTOR was born with the right time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005558/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom